Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

CM Westerhout, Eric Boersma

Research output: Contribution to journalArticleAcademic

7 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)49-58
Number of pages10
JournalExpert Opinion Drug Saf.
Volume2
Issue number1
DOIs
Publication statusPublished - 2003

Cite this